FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309185536> ?p ?o ?g. }

• W4309185536 endingPage "A023" @default.
• W4309185536 startingPage "A023" @default.
• W4309185536 abstract "Abstract Hyperthermia, the procedure of raising the temperature of a part of the entire body above normal for a defined period of time, is applied alone or as an adjunctive treatment to various established cancer treatment modalities such as radiotherapy and chemotherapy. Whole-Body Hyperthermia (WBHT), in contrast to local or regional hyperthermia, represents the only hyperthermia modality available for patients with disseminated malignancies. The biological rationale for the treatment of malignant disease by heat is driven by a number of reasons; a) the survival of cells depends on the temperature and duration of heating in a predictable and repeatable way; b) the tumor cell environment (such as hypoxia, poor nutrition, and low pH) that negatively influences the tumor cell killing by ionizing radiation and some chemotherapy regimens, is beneficially influenced by heat therapy; c) the differential sensitivity of normal and tumor cells to heat is dependent on cell type and environmental conditions; d) heat treatment enhances the biological effect of both radiation and chemotherapy agents. The biological rationale is based on a direct cell-killing effect at temperatures in the range of 41– 42°C. A systematic review of van der Horst et al, 2018, addressed clinical trials that used local or whole-body hyperthermia treatment (at variable temperatures) in pancreatic cancer patients. In those described trials, the weighted estimate of the treated population median overall survival was 11.7 compared to 5.6 for the control cohorts. In addition, locoregional hyperthermia (42-44°C) clinical trials showed that the weighted estimate median overall survival of the treated population was 15 months compared to 9 months in control cohorts. The MATTERS trial is a first in-human clinical investigation in advanced solid cancer patients or pancreatic adenocarcinoma patients (TxNxM1). The justification of the design is based on evaluation of pre-clinical data and clinical evaluation of clinical data, safety and/or performance of similar devices/therapies. The study is a mono-centric, non-randomized trial in which the safety and preliminary efficacy of whole-body hyperthermia will be evidenced. Well designed and performed early-stage correlative studies have the potential to strongly influence further clinical development of oncology clinical trials, and correlative data obtained from early stage trials has the potential to provide important guidance on the design and ultimate success of later stage trials. Blood samples will be collected for analysis of immunological panels (e.g. cytokines, chemokines), exosome research, RNA expression profiles. Urine will be collected for analysis of exosome research. The samples will be collected during different timepoints (before, during and after treatment). Citation Format: Ivana Gorbaslieva, Dana Mustafa, Robin Colenbier, Marc Peeters, Dirk Ysebaert, Vera Saldien, Luigi Brancato, Oleg Rudenko, Johan Van den Bossche, John Paul Bogers. First in-human, safety and preliminary efficacy study of (neo)adjuvant, model-based, whole-body hyperthermia treatment in advanced solid cancer patients or stage IV (TxNxM1) metastatic pancreatic adenocarcinoma patients: Liquid biopsies [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer; 2022 Sep 13-16; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2022;82(22 Suppl):Abstract nr A023." @default.
• W4309185536 created "2022-11-24" @default.
• W4309185536 creator A5016882902 @default.
• W4309185536 creator A5019503809 @default.
• W4309185536 creator A5024390084 @default.
• W4309185536 creator A5050995090 @default.
• W4309185536 creator A5052499647 @default.
• W4309185536 creator A5058910997 @default.
• W4309185536 creator A5071589826 @default.
• W4309185536 creator A5089617727 @default.
• W4309185536 creator A5090898921 @default.
• W4309185536 creator A5091617540 @default.
• W4309185536 date "2022-11-15" @default.
• W4309185536 modified "2023-09-25" @default.
• W4309185536 title "Abstract A023: First in-human, safety and preliminary efficacy study of (neo)adjuvant, model-based, whole-body hyperthermia treatment in advanced solid cancer patients or stage IV (TxNxM1) metastatic pancreatic adenocarcinoma patients: Liquid biopsies" @default.
• W4309185536 doi "https://doi.org/10.1158/1538-7445.panca22-a023" @default.
• W4309185536 hasPublicationYear "2022" @default.
• W4309185536 type Work @default.
• W4309185536 citedByCount "0" @default.
• W4309185536 crossrefType "journal-article" @default.
• W4309185536 hasAuthorship W4309185536A5016882902 @default.
• W4309185536 hasAuthorship W4309185536A5019503809 @default.
• W4309185536 hasAuthorship W4309185536A5024390084 @default.
• W4309185536 hasAuthorship W4309185536A5050995090 @default.
• W4309185536 hasAuthorship W4309185536A5052499647 @default.
• W4309185536 hasAuthorship W4309185536A5058910997 @default.
• W4309185536 hasAuthorship W4309185536A5071589826 @default.
• W4309185536 hasAuthorship W4309185536A5089617727 @default.
• W4309185536 hasAuthorship W4309185536A5090898921 @default.
• W4309185536 hasAuthorship W4309185536A5091617540 @default.
• W4309185536 hasConcept C121608353 @default.
• W4309185536 hasConcept C126322002 @default.
• W4309185536 hasConcept C143998085 @default.
• W4309185536 hasConcept C2776694085 @default.
• W4309185536 hasConcept C2779949491 @default.
• W4309185536 hasConcept C2780210213 @default.
• W4309185536 hasConcept C2780258809 @default.
• W4309185536 hasConcept C2908647359 @default.
• W4309185536 hasConcept C2909953478 @default.
• W4309185536 hasConcept C509974204 @default.
• W4309185536 hasConcept C535046627 @default.
• W4309185536 hasConcept C71924100 @default.
• W4309185536 hasConcept C99454951 @default.
• W4309185536 hasConceptScore W4309185536C121608353 @default.
• W4309185536 hasConceptScore W4309185536C126322002 @default.
• W4309185536 hasConceptScore W4309185536C143998085 @default.
• W4309185536 hasConceptScore W4309185536C2776694085 @default.
• W4309185536 hasConceptScore W4309185536C2779949491 @default.
• W4309185536 hasConceptScore W4309185536C2780210213 @default.
• W4309185536 hasConceptScore W4309185536C2780258809 @default.
• W4309185536 hasConceptScore W4309185536C2908647359 @default.
• W4309185536 hasConceptScore W4309185536C2909953478 @default.
• W4309185536 hasConceptScore W4309185536C509974204 @default.
• W4309185536 hasConceptScore W4309185536C535046627 @default.
• W4309185536 hasConceptScore W4309185536C71924100 @default.
• W4309185536 hasConceptScore W4309185536C99454951 @default.
• W4309185536 hasIssue "22_Supplement" @default.
• W4309185536 hasLocation W43091855361 @default.
• W4309185536 hasOpenAccess W4309185536 @default.
• W4309185536 hasPrimaryLocation W43091855361 @default.
• W4309185536 hasRelatedWork W1969578744 @default.
• W4309185536 hasRelatedWork W2005537476 @default.
• W4309185536 hasRelatedWork W2057062457 @default.
• W4309185536 hasRelatedWork W2319496893 @default.
• W4309185536 hasRelatedWork W2349340765 @default.
• W4309185536 hasRelatedWork W2356009571 @default.
• W4309185536 hasRelatedWork W2365966720 @default.
• W4309185536 hasRelatedWork W2370553050 @default.
• W4309185536 hasRelatedWork W2376347278 @default.
• W4309185536 hasRelatedWork W2391084975 @default.
• W4309185536 hasVolume "82" @default.
• W4309185536 isParatext "false" @default.
• W4309185536 isRetracted "false" @default.
• W4309185536 workType "article" @default.